Fan Yue, Liu Yinhui, Shao Chenyi, Jiang Chunyu, Wu Lijuan, Xiao Jing, Tang Li
Department of Microecology, College of Basic Medical Science, Dalian Medical University, Dalian 116041, China.
Department of Oral Pathology, College of Stomatology, Dalian Medical University, Dalian 116041, China.
Int J Mol Sci. 2025 Jun 7;26(12):5486. doi: 10.3390/ijms26125486.
Gut microbiota dysbiosis is intricately linked to metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), hyperlipidemia, and non-alcoholic fatty liver disease (NAFLD). Traditional Chinese medicine (TCM), particularly when combined with probiotic fermentation, offers a promising therapeutic strategy by modulating microbial balance and host metabolism. This narrative review synthesizes current research on probiotic-fermented herbal bioactives, focusing on their mechanisms in ameliorating metabolic diseases. Probiotic and bioactive compounds (e.g., berberine, polysaccharides) are highlighted for their roles in enhancing intestinal barrier function, regulating microbial metabolites like short-chain fatty acids (SCFAs), and reducing inflammation. Fermentation techniques improve the bioavailability of TCM components while reducing toxicity, as seen in fermented and . Despite promising results, challenges include the complexity of microbiota-host interactions and variability in TCM standardization. Future directions emphasize integrating multi-omics technologies and personalized approaches to optimize probiotic-fermented TCM therapies. This review underscores the potential of combining traditional herbal wisdom with modern biotechnology to address metabolic disorders, which pose significant global health challenges, through a "gut microbiota-metabolism" axis. Emerging evidence highlights the critical role of gut microbiota dysbiosis in the pathogenesis of these conditions. TCM has shown promise in modulating gut microbiota to restore metabolic homeostasis. This review synthesizes current research on TCM-derived interventions, such as herbal compounds, probiotics, and fermentation techniques, that target gut microbiota to ameliorate metabolic disorders. We discuss mechanisms of action, including prebiotic effects, enhancement of intestinal barrier function, and regulation of microbial metabolites, while addressing the limitations and future directions of TCM-based therapies.
肠道微生物群失调与肥胖、2型糖尿病(T2DM)、高脂血症和非酒精性脂肪性肝病(NAFLD)等代谢紊乱密切相关。传统中医(TCM),特别是与益生菌发酵相结合时,通过调节微生物平衡和宿主代谢提供了一种有前景的治疗策略。这篇叙述性综述综合了目前关于益生菌发酵草药生物活性成分的研究,重点关注它们改善代谢疾病的机制。益生菌和生物活性化合物(如黄连素、多糖)因其在增强肠道屏障功能、调节短链脂肪酸(SCFAs)等微生物代谢产物以及减轻炎症方面的作用而受到关注。发酵技术提高了中药成分的生物利用度,同时降低了毒性,如在发酵的[具体物质1]和[具体物质2]中所见。尽管取得了有前景的结果,但挑战包括微生物群与宿主相互作用的复杂性以及中药标准化的变异性。未来的方向强调整合多组学技术和个性化方法,以优化益生菌发酵的中医疗法。这篇综述强调了将传统草药智慧与现代生物技术相结合,通过“肠道微生物群 - 代谢”轴应对代谢紊乱的潜力,代谢紊乱对全球健康构成重大挑战。新出现的证据突出了肠道微生物群失调在这些疾病发病机制中的关键作用。中医在调节肠道微生物群以恢复代谢稳态方面已显示出前景。这篇综述综合了目前关于源自中医的干预措施的研究,如草药化合物、益生菌和发酵技术,这些措施针对肠道微生物群以改善代谢紊乱。我们讨论了作用机制,包括益生元效应、肠道屏障功能的增强以及微生物代谢产物的调节,同时解决了基于中医的疗法的局限性和未来方向。